Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
 |
2024 –2031 |
 |
USD 824.75 Million |
 |
USD 1,088.56 Million |
 |
% |
|
|
Global Pregabalin Market, By Dosage Forms (Oral Capsule, Oral Solution, Oral Tablet, Extended Release), Application (Epilepsy, Neuropathic Pain, Anxiety Disorder, Others), Drug Class (Fibromyalgia Agents, Anticonvulsants, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2031.
Pregabalin is an anticonvulsant medication that can be used to treat epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. It works by reducing the pain signals delivered by injured nerves throughout the body. As per the International Association of the Study of Pain's Global Year against Neuropathic Pain 2014-2015 study, approximately 7% to 8% of adults suffer from chronic pain with neuropathic characteristics.
Data Bridge Market Research analyzes that the global pregabalin market which was USD 824.75 million in 2023, is likely to reach USD 1,088.56 million by 2031, and is expected to undergo a CAGR of 3.53% during the forecast period. “Oral” dominates the dosage form segment of the market due to rising demand of pregabalin oral dosage form. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Dosage Forms (Oral Capsule, Oral Solution, Oral Tablet, Extended Release), Application (Epilepsy, Neuropathic Pain, Anxiety Disorder, Others), Drug Class (Fibromyalgia Agents, Anticonvulsants, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey, Rest of Europe, China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, Rest of Asia-Pacific, South Africa, Rest of Middle East and Africa, Brazil, Rest of South America
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Zydus Cadila (India), Lupin (India), Amneal Pharmaceuticals LLC. (U.S.), Cipla Inc. (U.S.), Torrent Pharmaceuticals Ltd. (India), Aurobindo Pharma (India), Glenmark Pharmaceuticals Limited (India), Medley Pharmaceuticals Ltd. (India), Genesis Biotec Inc. (India), Biomax Pharmaceutical Company (UK), ZCL Chemicals Ltd. (India), Olon S.p.A. (Italy), HIKAL Ltd. (India)
|
|
Market Opportunities
|
|
Market Definition
Pregabalin is an anticonvulsant and anxiolytic medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome, and generalized anxiety disorder. It's an epilepsy medication that's used to treat partial seizures. It functions by lowering nerve activity and lowering pain. Anti-epileptic medicines (AEDs) such as Lyrica (pregabalin) and Topamax (topiramate) are used to prevent epileptic seizures. Lyrica is also indicated to treat diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia neuropathic pain.
Drivers
The surging prevalence of epilepsy is a major factor driving the pregabalin market's growth rate during the forecast period. According to the World Health Organization (WHO), an estimated 50 million people are living with epilepsy globally in 2019, with up to 75 percent of them living in resource-poor countries with little or no access to treatment or medical services. Furthermore, approximately 80% of people with epilepsy live in low- and middle-income nations. In the treatment of epilepsy, pregabalin stops seizures by reducing aberrant electrical activity in the brain.
The growing application of Lyrica is anticipated to propel the market's growth rate. Lyrica (pregabalin) is a fibromyalgia drug approved by the US Food and Drug Administration. Fibromyalgia is a chronic illness that causes long-term, widespread muscle pain and soreness and sleeping difficulties and exhaustion. Lyrica is a drug used to treat nerve signals. Fibromyalgia affects over 4 million individuals in the United States, or about 2% of the adult population, according to the Centers for Disease Control and Prevention (CDC). The etiology of fibromyalgia is unknown, but it can be effectively treated and managed. Lyrica has long been used to treat nerve pain in shingles or diabetic neuropathy patients. The drug Lyrica is also used to treat partial seizures.
Neuropathic pain and certain anxiety disorders are more prevalent in the elderly population. With a growing global aging demographic, there is an increased demand for medications that address age-related health issues. Pregabalin's effectiveness in managing pain and anxiety makes it a valuable option for this demographic, thereby driving market growth.
Surging focus on improving the condition of healthcare facilities and improving the overall healthcare infrastructure is another important factor fostering the growth of the market. The rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.
Opportunities
Investing in research and development to explore new therapeutic indications for pregabalin could open up new markets and revenue streams. Identifying and validating additional medical conditions where pregabalin demonstrates efficacy could lead to expanded usage and increased market share.
Collaboration between pharmaceutical companies, research institutions, and healthcare providers can create synergies and drive market growth. Partnerships for clinical trials, marketing initiatives, or distribution agreements can enhance the visibility and accessibility of pregabalin, particularly in regions with unmet medical needs.
Restraints
The expiration of patents for branded pregabalin products can lead to increased competition from generic manufacturers. Generic alternatives are typically more affordable, which can negatively impact the market share and revenue of the original drug.
Pregabalin, like any medication, may have side effects, and concerns about its safety profile could pose a restraint. As more information becomes available about potential side effects or adverse reactions, healthcare providers and patients may become more cautious in prescribing and using pregabalin.
Challenges
The pregablin market has become highly competitive with the presence of established companies and new entrants. The saturation of the market could pose challenges for companies in terms of differentiation, pricing, and market share.
Healthcare systems worldwide are under pressure to contain costs, and this can affect the pricing and reimbursement of pharmaceuticals, including pregabalin. Payers may push for lower prices, impacting the revenue potential for manufacturers. Navigating pricing negotiations and demonstrating the value proposition of pregabalin in terms of efficacy and patient outcomes can be challenging.
This pregabalin market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pregabalin market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
The pregabalin market is segmented on the basis of drug class, application, dosage forms, end-users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Application
Drug Class
Dosage Forms
End-Users
Distribution Channel
The pregabalin market is analyzed and market size insights and trends are provided by country, drug class, application, dosage forms, end-users and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, South Africa, U.A.E., Israel, Egypt, and rest of Middle East and Africa.
North America is expected to dominate the market due to the presence of major key players and rising healthcare expenditure will further propel the market's growth rate in this region. In addition, an increase in the number of research and development activities will further propel the market's growth rate in this region.
Asia-Pacific is expected to grow during the forecast period due to the surging prevalence of convulsions and anxiety disorders in this region. Also, the development of healthcare infrastructure and rising geriatric population will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The Pregabalin market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Pregabalin market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Pregabalin market. The data is available for historic period 2010-2020.
The pregabalin market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to pregabalin market.
Some of the major players operating in the pregabalin market are:
SKU-
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
The market is segmented based on , By Dosage Forms (Oral Capsule, Oral Solution, Oral Tablet, Extended Release), Application (Epilepsy, Neuropathic Pain, Anxiety Disorder, Others), Drug Class (Fibromyalgia Agents, Anticonvulsants, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2031. .
The Global Pregabalin Market size was valued at USD 824.75 USD Million in 2023.
The Global Pregabalin Market is projected to grow at a CAGR of 3.53% during the forecast period of 2024 to 2031.
The major players operating in the market include Pfizer Inc. ,GlaxoSmithKline plc ,Novartis AG ,Mylan N.V. ,Teva Pharmaceutical Industries Ltd. ,Sanofi ,F. Hoffmann-La Roche Ltd. ,Aurobindo Pharma ,Lupin ,Zydus Cadila ,Amneal Pharmaceuticals LLC. ,Cipla Inc. ,Torrent Pharmaceuticals Ltd. ,Glenmark Pharmaceuticals Limited ,Medley Pharmaceuticals Ltd. ,Genesis Biotec Inc. ,Biomax Pharmaceutical Company ,ZCL Chemicals Ltd. ,Olon S.p.A. ,HIKAL Ltd. .
The market report covers data from the U.S., Canada, Mexico, U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey, Rest of Europe, China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, Rest of Asia-Pacific, South Africa, Rest of Middle East and Africa, Brazil, Rest of South America.
